Recent News
September 1, 2009
MABCURE CEO ARTICLE FEATURED IN THE SEPTEMBER ISSUE OF GENŽ
» MORE
August 25, 2009
MABCURE FEATURED IN BIOWORLDŽ TODAY
» MORE
August 18, 2009
ARTICLE BY MABCURE CEO -- TUMOUR-SPECIFIC MARKERS: THE HOLY GRAIL OF CANCER DIAGNOSTICSG
» MORE
August 7, 2009
MABCURE APPEARS IN ARTICLE ON "THE USE OF BIOMOLECULES IN DIAGNOSTIC TESTING
» MORE
April 27, 2009
MABCURE
WELCOMES DR. DAVID S. FRANK AS NEW MEMBER OF THE BOARD OF DIRECTORS
» MORE
April 1, 2009
MABCURE ESTABLISHES RESEARCH FACILITIES ON THE CAMPUS OF HASSELT UNIVERSITY
» MORE
October 30th, 2008
MABCURE ESTABLISHES BELGIAN SUBSIDIARY AND RELOCATES HEADQUARTERS TO BELGIUM
» MORE
July 11th, 2008
MABCURE COMPLETES KEY
ACQUISITION
» MORE
June 27th, 2008
MABCURE CLOSES US $1.3
MILLION PRIVATE PLACEMENT
» MORE
MabCure, Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as a largely incurable disease. MabCure's primary mission is to develop novel diagnostics for the early detection of cancer when the disease is still localized and treatable, and where the chances for cure are greater than 90 percent.
MabCure’s longer term goals are to provide physicians with novel antibodies and drugs that effectively attack only cancer cells while sparing normal tissue and minimize toxic side effects.
[Video] See President & CEO, Dr. Amnon Gonenne, talk about MabCure and its technology.